Facteurs prédictifs de survenue de décompensation au cours de la cholangite biliaire primitive

Jammeli, C.; Gdoura, H.; Boudabous, M.; Chtourou, L.; Amouri, A.; Mnif, L.; Tahri, N.

doi:10.1016/j.revmed.2019.10.252

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, studies are inconsistent, and the exact incidence of HCC in this disease is still poorly understood. Some studies suggest that HCC may be as common in primary biliary cirrhosis as in other causes of cirrhosis [31]- [37]. Concerning the predictive factors of non-response to UDCA ( Table 9) , the results of the univariate analysis showed that advanced age at diagnosis and gender were not significantly associated with an incomplete response to treatment.…”

Section: Discussionmentioning

confidence: 97%

“…These systemic manifestations may precede the specific symptomatology of PBC, leading to its discovery. [31]- [40]. The frequency of these associated autoimmune pathologies varies according to the authors from 15 to 84%.…”

Section: Discussionmentioning

confidence: 99%

“…Treatment of overlap syndrome consists of combining UDCA with the immunosuppressive therapy usually recommended for HAI (corticosteroids and azathioprine). When conventional immunosuppressive agents are ineffective, second-line agents are prescribed, such as cyclosporin, tacrolimus and mycophenolate mofetil [31], [47], [48], [49], [50]In our series, patients diagnosed with overlap syndrome were placed on UDCA with corticosteroid therapy and azathioprine.Complications frequently arise during the course of PBC. Portal hypertension is a common complication.…”

Section: Discussionmentioning

confidence: 99%

“…Portal hypertension is a common complication. Its prevalence is estimated at between 2.5 and 6% [31]- [50]. It may be responsible for rupture of esophageal varices, ascites or hepatic encephalopathy.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Is primary biliary cholangitis still a challenge? Experience of Hassan II University Hospital FES Morocco

Imane ATMANI,

Maria Lahlali,

Asmae Lamine

et al. 2024

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Introduction: Primary biliary cholangitis is a chronic autoimmune hepatopathy and the leading cause of intrahepatic cholestasis. Treatment is mainly based on ursodesoxycholic acid. The aim of our work is to study the epidemiological, clinical and evolutionary profile of PBC, and to determine the factors predictive of a poor response to UDCA in our context. Materials and methods: This is a retrospective descriptive and analytical study of all cases of PBC followed in our training program from June 2012 to February 2023. Results: We recorded all clinical, diagnostic, therapeutic and evolutionary aspects of 70 cases of PBC. Ninety-two percent ( n= 65) were women. The mean age was 57.3 [24-83] years. The circumstances of discovery were dominated by pruritus, and jaundice. M2-type anti-mitochondrial antibodies were positive in 91.4% of cases. 52.14% of cases had associated autoimmune diseases. Treatment was based on UDCA in all cases, combined with corticosteroids and immunosuppressants for patients with overlap syndrome. A biochemical response after one year of treatment according to Paris II criteria was found in 62.85% (44 cases). In univariate analysis, the factors associated with poor response to treatment were : Discovery of cirrhosis at diagnosis , Decompensated cirrhosis , presence of overlap syndrome , poor compliance with UDCA due to non-availability of medication , initial bilirubin level above 30 mg/l , hypoalbuminemia below 35 g/l. Conclusion: Our study shows the frequency of cirrhosis in PBC, which may explain the low response rate to UDCA, a drug that remains difficult to obtain in our Moroccan context, making prognosis poor and management difficult.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%